Global Gingivitis Treatment Market reaching USD 11.19 Billion by 2033 at a CAGR of 4.8%

Gingivitis Treatment Market
Gingivitis Treatment Market

The global gingivitis treatment market is worth USD 7 Billion as of now and expected to reach USD 11.19 Billion by the year 2033 at a CAGR of 4.8% between 2023 and 2033.

The end-consumers are turning out to be all the more conscious regarding an inseparable link between health on the whole and oral health; thereby resulting in an ever-increasing demand for oral care services as well as products.

Also, there is a tremendous rise in the number of online sales channels, which foster the growth further. With gum diseases growing in frequency, there is no stoppage to the gingivitis treatment market.

Gingivitis causes bleeding and inflammation of gums. Moreover, if not treated on time, it could progress to all the more severe form of gum disease. The WHO states that gingivitis affects close to 90% of the population worldwide.

Poor oral hygiene, aging, smoking, chewing of tobacco result in gingivitis. However, the good part is that awareness in this regard is rising. As such, apart from drugs, lasers are getting used for treating the disease. This factor is expected to enhance the popularity of gingivitis treatment market going forward.

At the same time, the fact that gingivitis treatment is costly could hamper the gingivitis treatment market going forward. Also, compliance to regulations in this regard is challenging. So, small companies may have to think twice before venturing herein.

Future Market Insights has entailed these facts with future prospects in its latest market study entitled ‘Gingivitis Treatment Market’. It has its team of analysts and consultants to execute using an eagle’s eye view in its primary, secondary, and tertiary modes of research.

“With growing awareness regarding oral hygiene, the global gingivitis treatment market is expected to go great guns in the forecast period”, says an analyst from Future Market Insights.

Competitive Treatment:

  • It was announced in October 2022 that rapid test regarding gum disease was being developed at the University of Birmingham. The basic purpose of this probe is that of being used in point-of-care settings like dental pharmacies or surgeries. It could also help in detection of lung or heart disease at an early stage, along with rheumatoid arthritis and type 2 diabetes. On these grounds, Professor Tim Albrecht from School of Chemistry and Dr. Melissa Grant from the School of Dentistry at the University have developed a unique technique of precise assessment of gum disease using sample of saliva.
  • The other players in gingivitis treatment market include Fibrocell Sciences, Eli Lilly & Company, Dentsply International, Align technology, Ultradent Products Inc., 3M Company, Glidewell Laboratories, Nobel Biocare Holdings AG, Kaken Pharmaceutical, Orapharma, and Valeant Pharmaceuticals Inc. They are engaging in various modes of expansion like new product launch, mergers, acquisitions, partnerships, and joint ventures to make a mark for themselves in gingivitis treatment market.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

What does the Report say?

  • The research study is based on drug class (veetids, erythrocin, minocycline, doxycycline, clindamycin, chlorhexidine, acetaminophen, ibuprofen, and lidocaine), route of administration (oral and topical), and end-user (hospital pharmacy, retail pharmacy, and online pharmacy).
  • With growing prevalence of gum disease, the global gingivitis treatment market is expected to grow irresistibly in the forecast period.

Key Companies Profiled:

Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals Int.

Key Segments Profiled in the Gingivitis Treatment Industry Survey:

Drug Class:

  • Veetids
  • Erythrocin
  • Minocycline
  • Doxycycline
  • Clindamycin
  • Chlorhexidine
  • Acetaminophen
  • Ibuprofen
  • Lidocaine

Route of Administration:

  • Oral
  • Topical

End-User:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these